Washburn, R.L.; Hibler, T.; Kaur, G.; Sabu-Kurian, A.; Landefeld, A.; Dufour, J.M.
Immunoregulatory Sertoli Cell Allografts Engineered to Express Human Insulin Survive Humoral-Mediated Rejection. Int. J. Mol. Sci. 2022, 23, 15894.
https://doi.org/10.3390/ijms232415894
AMA Style
Washburn RL, Hibler T, Kaur G, Sabu-Kurian A, Landefeld A, Dufour JM.
Immunoregulatory Sertoli Cell Allografts Engineered to Express Human Insulin Survive Humoral-Mediated Rejection. International Journal of Molecular Sciences. 2022; 23(24):15894.
https://doi.org/10.3390/ijms232415894
Chicago/Turabian Style
Washburn, Rachel L., Taylor Hibler, Gurvinder Kaur, Anna Sabu-Kurian, Alissa Landefeld, and Jannette M. Dufour.
2022. "Immunoregulatory Sertoli Cell Allografts Engineered to Express Human Insulin Survive Humoral-Mediated Rejection" International Journal of Molecular Sciences 23, no. 24: 15894.
https://doi.org/10.3390/ijms232415894
APA Style
Washburn, R. L., Hibler, T., Kaur, G., Sabu-Kurian, A., Landefeld, A., & Dufour, J. M.
(2022). Immunoregulatory Sertoli Cell Allografts Engineered to Express Human Insulin Survive Humoral-Mediated Rejection. International Journal of Molecular Sciences, 23(24), 15894.
https://doi.org/10.3390/ijms232415894